Who We Are

Amplyx develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

A weakened immune system can arise over the course of treatment for cancer and other critical illnesses, or following organ or stem cell transplantation, leading to possibly life-threatening secondary illnesses.

Our clinical-stage product candidates, fosmanogepix (APX001) and MAU868, have the potential to protect those who are vulnerable to secondary illnesses, and transform standard of care treatments for immunocompromised patients.

Fosmanogepix

Fosmanogepix is a novel antifungal agent being developed for the treatment of serious fungal infections that threaten those who are immunocompromised, such as people receiving cancer treatments.

Learn More

MAU868

MAU868 is a monoclonal antibody that potently neutralizes the BK virus, the leading cause of allograft loss in kidney transplant recipients and the cause of a devastating disease in bone marrow recipients.

Learn More

"

“Too often, the recovery of people struggling to overcome cancer or a lifesaving transplant is put at risk by the very treatments necessary to save their lives. Our mission is to bring innovative therapies to these vulnerable, immunocompromised patients and keep them on the path to renewed health.”

Ciara Kennedy, Ph.D.
President and CEO, Amplyx Pharmaceuticals